Cited by 243Glioma Diagnosis and TreatmentNeuroblastoma Research and TreatmentsAcute Lymphoblastic Leukemia research

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)

Open access

Gajjar, Amar, Robinson, Giles W., Smith, Kyle S., Lin, Tong, Merchant, Thomas E., Chintagumpala, Murali, Mahajan, Anita, Su, Jack, Bouffet, Eric, Bartels, Ute, Schechter, Tal, Hassall, Tim, Robertson, Thomas, Nicholls, Wayne, Gururangan, Sridharan, Schroeder, Kristin, Sullivan, Michael, Wheeler, Greg, Hansford, Jordan R., Kellie, Stewart J., McCowage, Geoffrey, Cohn, Richard, Fisher, Michael J., Krasin, Matthew J., Stewart, Clinton F., Broniscer, Alberto, Buchhalter, Ivo, Tatevossian, Ruth G., Orr, Brent A., Neale, Geoff, Klimo, Paul, Boop, Frederick, Srinivasan, Ashok, Pfister, Stefan M., Gilbertson, Richard J., Onar-Thomas, Arzu, Ellison, David W., Northcott, Paul A.·2021·Journal of Clinical Oncology

DOI 10.1200/jco.20.01372PMC PMC10166353

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: SJMB03 (ClinicalTrials.gov identifier: NCT00085202 ) was a phase III risk-adapted trial that aimed to determine the frequency and clinical significance of biological variants and genetic alterations in medulloblastoma. PATIENTS AND METHODS: Patients 3-21 years old were stratified into average-risk and high-risk treatment groups based on metastatic status and extent of resection. Medulloblastomas were molecularly classified into subgroups (Wingless [WNT], Sonic Hedgehog [SHH], group 3, and group 4) and subtypes based on DNA methylation profiles and overlaid with gene mutations from next-generation sequencing. Coprimary study end points were (1) to assess the relationship between ERBB2 protein expression in tumors and progression-free survival (PFS), and (2) to estimate the frequency of mutations associated with WNT and SHH tumors. Clinical and molecular risk factors were evaluated, and the most robust were used to model new risk-classification categories. RESULTS: Three hundred thirty eligible patients with medulloblastoma were enrolled. Five-year PFS was 83.2% (95% CI, 78.4 to 88.2) for average-risk patients (n = 227) and 58.7% (95% CI, 49.8 to 69.1) for high-risk patients (n = 103). No association was found between ERBB2 status and PFS in the overall cohort ( P = .74) or when patients were stratified by clinical risk ( P = .71). Mutations in CTNNB1 (96%), DDX3X (37%), and SMARCA4 (24%) were most common in WNT tumors and PTCH1 (38%), TP53 (21%), and DDX3X (19%) in SHH tumors. Methylome profiling classified 53 WNT (17.4%), 48 SHH (15.7%), 65 group 3 (21.3%), and 139 group 4 (45.6%) tumors. A comprehensive clinicomolecular risk factor analysis identified three low-risk groups (WNT, low-risk SHH, and low-risk combined groups 3 and 4) with excellent (5-year PFS > 90%) and two very high-risk groups (high-risk SHH and high-risk combined groups 3 and 4) with poor survival (5-year PFS < 60%). CONCLUSION: These results establish a new risk stratification for future medulloblastoma trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.20.01372

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

DNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chávez, L., Reuß, D., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,114
Self-citation
Molecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936
Self-citation
Medulloblastoma Comprises Four Distinct Molecular Variants
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S. C., Bouffet, É., Clifford, S. C., Hawkins, C. E., French, P. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4324 · Cited by 1,353
Self-citation
Intertumoral Heterogeneity within Medulloblastoma Subgroups
Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.005 · Cited by 1,219
Self-citation
The whole-genome landscape of medulloblastoma subtypes
Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., et al. (2017) · Nature · doi:10.1038/nature22973 · Cited by 1,112
Self-citation
Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma
Packer, R. J., Gajjar, A. J., Vézina, G., Rorke-Adams, L. B., Burger, P. C., Robertson, P. L., Bayer, L. A., Lafond, D. A., Donahue, B. R., Marymont, M. H., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4980 · Cited by 985
Self-citation
Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial
Gajjar, A. J., Chintagumpala, M., Ashley, D. M., Kellie, S. J., Kun, L. E., Merchant, T. E., Woo, S. Y., Wheeler, G., Ahern, V., Krasin, M. J., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70867-1 · Cited by 951
Self-citation
Subgroup-specific structural variation across 1,000 medulloblastoma genomes
Northcott, P. A., Shih, D. J. H., Peacock, J., Garzia, L., Morrissy, A. S., Zichner, T., Stütz, A. M., Korshunov, A., Reimand, J., Schumacher, S. E., et al. (2012) · Nature · doi:10.1038/nature11327 · Cited by 887
Self-citation
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations
Rausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865
Self-citation
Novel mutations target distinct subgroups of medulloblastoma
Robinson, G. W., Parker, M. D., Kranenburg, T. A., Lu, C., Chen, X. '., Ding, L., Phoenix, T. N., Hedlund, E., Wei, L., Zhu, X., et al. (2012) · Nature · doi:10.1038/nature11213 · Cited by 853
Self-citation

Flagged first, then by citations

Show all 28 references

Research works printed but not linked: 1

Gilbertson RJ, 1998, Cancer Res, 58, 3932

Sorted by citations

Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours
Horbinski, C., Berger, T., Packer, R. J., & Wen, P. Y. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00679-w · Cited by 312
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies
Liu, A. P. Y., Smith, K. S., Kumar, R., Paul, L., Bihannic, L., Lin, T., Maaß, K. K., Pajtler, K. W., Chintagumpala, M., Su, J. M. F., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.012 · Cited by 177
Self-citation
Unified rhombic lip origins of group 3 and group 4 medulloblastoma
Smith, K. S., Bihannic, L., Gudenas, B. L., Haldipur, P., Tao, R., Gao, Q., Li, Y., Aldinger, K. A., Iskusnykh, I. Y., Chizhikov, V. V., et al. (2022) · Nature · doi:10.1038/s41586-022-05208-9 · Cited by 168
Self-citation
Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century
Ehrhardt, M. J., Krull, K. R., Bhakta, N. H., Liu, Q., Yasui, Y., Robison, L. L., & Hudson, M. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00802-w · Cited by 133
Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma
Kumar, R., Smith, K. S., Deng, M. Y., Terhune, C., Robinson, G. W., Orr, B. A., Liu, A. P. Y., Lin, T., Billups, C. A., Chintagumpala, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01359 · Cited by 86
Self-citation
Medulloblastoma: Current Perspectives and Recent Advances
Choi, J. Y. (2023) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2022.0046 · Cited by 75
Medulloblastoma in the Modern Era: Review of Contemporary Trials, Molecular Advances, and Updates in Management
Lazow, M., Palmer, J. D., Fouladi, M., & Salloum, R. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01273-0 · Cited by 58
Update on Cancer Predisposition Syndromes and Surveillance Guidelines for Childhood Brain Tumors
Hansford, J. R., Das, A., McGee, R. B., Nakano, Y., Brzezinski, J. J., Scollon, S., Rednam, S. P., Schienda, J., Michaeli, O., Kim, S. Y., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-4033 · Cited by 51
Self-citation
New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma
Fang, F. Y., Rosenblum, J. S., Ho, W. S., & Heiss, J. D. (2022) · Cancers · doi:10.3390/cancers14092285 · Cited by 48
Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a “MEMMAT-like” Metronomic Antiangiogenic Approach
Slavc, I., Mayr, L., Stepien, N. M., Gojo, J., Lippolis, M. A., Azizi, A. A., Chocholous, M., Baumgartner, A., Hedrich, C., Holm, S., et al. (2022) · Cancers · doi:10.3390/cancers14205128 · Cited by 47
Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment
Ray, S., Chaturvedi, N. K., Bhakat, K. K., Rizzino, A., & Mahapatra, S. (2021) · Diagnostics · doi:10.3390/diagnostics12010061 · Cited by 49
Developmental basis of SHH medulloblastoma heterogeneity
Gold, M. P., Ong, W., Masteller, A. M., Ghasemi, D. R., Galindo, J., Park, N. R., Huynh, N. C., Donde, A., Pister, V. I., Saurez, R. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44300-0 · Cited by 36
Primary cilia control translation and the cell cycle in medulloblastomaPreprint
Youn, Y. H., Hou, S., Wu, C., Kawauchi, D., Orr, B. A., Robinson, G. W., Finkelstein, D., Taketo, M. M., Gilbertson, R. J., Roussel, M. F., et al. (2022) · Genes & Development · doi:10.1101/gad.349596.122 · Cited by 36
Self-citation
Adolescents and Young Adults With Cancer: CNS Tumors
Wu, J., Heidelberg, R. E., & Gajjar, A. J. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01747 · Cited by 38
Self-citation
Association Between Brain Substructure Dose and Cognitive Outcomes in Children With Medulloblastoma Treated on SJMB03: A Step Toward Substructure-Informed Planning
Acharya, S., Guo, Y., Patni, T., Li, Y., Wang, C., Gargone, M., Ashford, J. M., Wilson, L. J., Faught, A., Reddick, W. E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01480 · Cited by 37
Self-citation
A spatial cell atlas of neuroblastoma reveals developmental, epigenetic and spatial axis of tumor heterogeneityPreprint
Patel, A. G., Ashenberg, O., Collins, N. B., Segerstolpe, Å., Jiang, S., Slyper, M., Huang, X., Caraccio, C., Jin, H., Sheppard, H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.07.574538 · Cited by 39
Self-citation
WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification
Tran, S., & Bielle, F. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000903 · Cited by 32
Posterior fossa tumors in children: current insights
Formentin, C., Joaquim, A. F., & Ghizoni, E. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-05189-5 · Cited by 33
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions
Lim-Fat, M. J., Bennett, J., Ostrom, Q. T., Touat, M., Franceschi, E., Schulte, J. D., Bindra, R. S., Fangusaro, J., Dhall, G., Nicholson, J. C., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae186 · Cited by 36
Self-citation
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors
Horbinski, C., Solomon, D. A., Lukas, R. V., Packer, R. J., Brastianos, P. K., Wen, P. Y., Snuderl, M., Berger, M. S., Chang, S. M., Fouladi, M., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.5506 · Cited by 41
Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children
Keilty, D., Khandwala, M., Liu, Z. A., Papaioannou, V., Bouffet, É., Hodgson, D., Yee, R., Cushing, S., Laperriere, N., Ahmed, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00899 · Cited by 30
Self-citation
Molecular classification improves therapeutic options for infants and young children with medulloblastoma
Bagchi, A., Dhanda, S. K., Dunphy, P., Sioson, E., & Robinson, G. W. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7024 · Cited by 28
Self-citation
High-Dose Chemotherapy in Children with Newly Diagnosed Medulloblastoma
Lafay‐Cousin, L., & Dufour, C. (2022) · Cancers · doi:10.3390/cancers14030837 · Cited by 27
Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group
Cooney, T., Lindsay, H., Leary, S. E. S., & Wechsler‐Reya, R. J. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100861 · Cited by 28
Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country
Amayiri, N. Y., Swaidan, M., Ibrahimi, A., Hirmas, N., Musharbash, A. F., Bouffet, É., Al-Hussaini, M. A., & Ramaswamy, V. (2021) · JCO Global Oncology · doi:10.1200/go.21.00127 · Cited by 25
Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children’s Oncology Group
Mazewski, C., Leary, S. E. S., Kang, G., Li, B. K., Kellie, S. J., Hayes, L. L., Shaw, D., Ho, B., Reddy, A. T., Gossett, J. M., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf132 · Cited by 24
Self-citation
Predictors of Cognitive Performance Among Infants Treated for Brain Tumors: Findings From a Multisite, Prospective, Longitudinal Trial
Ali, J. S., Ashford, J. M., Swain, M. A., Harder, L. L., Carlson-Green, B., Miller, J. M., Wallace, J., Kaner, R., Billups, C. A., Onar‐Thomas, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01687 · Cited by 24
Self-citation
The Clinical Applications of Liquid Biopsies in Pediatric Brain Tumors: A Systematic Literature Review
Greuter, L., Frank, N. A., Guzman, R. G., & Soleman, J. (2022) · Cancers · doi:10.3390/cancers14112683 · Cited by 24
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification
Goddard, J., Castle, J., Southworth, E., Fletcher, A., Crosier, S., Martín‐Guerrero, I., García-Ariza, M., Navajas, A., Masliah‐Planchon, J., Bourdeaut, F., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02566-0 · Cited by 25
Self-citation
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Gajjar, A. J., Mahajan, A., Bale, T., Bowers, D. C., Canan, L., Chi, S. N., Cluster, A. S., Cohen, K. J., Cole, B., Coven, S. L., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0012 · Cited by 23
Self-citation
Clinical outcome of pediatric medulloblastoma patients with Li–Fraumeni syndrome
Kolodziejczak, A. S., Guerrini‐Rousseau, L., Masliah‐Planchon, J., Ecker, J., Selt, F., Mynarek, M., Obrecht, D., Sill, M., Autry, R. J., Stutheit-Zhao, E., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad114 · Cited by 26
Self-citation
Mean global DNA methylation serves as independent prognostic marker in IDH-wildtype glioblastoma
Eckhardt, A., Drexler, R., Schoof, M., Struve, N., Capper, D., Jelgersma, C., Onken, J., Harter, P. N., Weber, K. J., Divé, I., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad197 · Cited by 23
Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors
Ronsley, R. J., Karvonen, K. A., Cole, B., Paulson, V., Stevens, J., Crotty, E. E., Hauptman, J. S., Lee, A. S., Stasi, S. M., Lockwood, C. M., et al. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04645-y · Cited by 22
Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study
Gaab, C., Adolph, J. E., Tippelt, S., Mikasch, R., Obrecht, D., Mynarek, M., Rutkowski, S., Pfister, S. M., Milde, T., Witt, O., et al. (2022) · Cancers · doi:10.3390/cancers14030471 · Cited by 22
Self-citation
Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level
Godbole, S., Voß, H., Gocke, A., Schlumbohm, S., Schumann, Y., Peng, B., Mynarek, M., Rutkowski, S., Dottermusch, M., Dorostkar, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50554-z · Cited by 27
Self-citation
Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data
Hansford, J. R., Huang, J., Endersby, R., Dodgshun, A. J., Li, B. K., Hwang, E. I., Leary, S. E. S., Gajjar, A. J., von Hoff, K., Wells, O., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac056 · Cited by 21
Self-citation
Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts
Mynarek, M., Obrecht, D., Sill, M., Sturm, D., Kloth‐Stachnau, K., Selt, F., Ecker, J., von Hoff, K., Juhnke, B.-O., Goschzik, T., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02522-4 · Cited by 24
Self-citation
A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma
Cohen, K. J., Munjapara, V., Aguilera, D. G., Castellino, R. C., Stapleton, S. L., Landi, D. B., Ashley, D. M., Rodríguez, F. J., Hawkins, C. E., Yang, E., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0348 · Cited by 21
The comparison of acute toxicities associated with craniospinal irradiation between photon beam therapy and proton beam therapy in children with brain tumors
Uemura, S., Demizu, Y., Hasegawa, D., Fujikawa, T., Inoue, S., Nishimura, A., Tojyo, R., Nakamura, S., Kozaki, A., Saito, A., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4553 · Cited by 20
Toxicity and Clinical Results after Proton Therapy for Pediatric Medulloblastoma: A Multi-Centric Retrospective Study
Ruggi, A., Melchionda, F., Sardi, I., Pavone, R., Meneghello, L., Kitanovski, L., Zaletel, L. Z., Farace, P., Zucchelli, M., Scagnet, M., et al. (2022) · Cancers · doi:10.3390/cancers14112747 · Cited by 19
The clinical significance of sub-total surgical resection in childhood medulloblastoma: a multi-cohort analysis of 1100 patients
Keeling, C., Davies, S., Goddard, J., Ramaswamy, V., Schwalbe, E. C., Bailey, S., Hicks, D., & Clifford, S. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102469 · Cited by 19
Simultaneous Ultra-Sensitive Detection of Structural and Single Nucleotide Variants Using Multiplex Droplet Digital PCR in Liquid Biopsies from Children with Medulloblastoma
Arthur, C., Jylhä, C., de Ståhl, T. D., Shamikh, A., Sandgren, J., Rosenquist, R., Nordenskjöld, M., Harila‐Saari, A. H., Barbany, G., Sandvik, U., et al. (2023) · Cancers · doi:10.3390/cancers15071972 · Cited by 20
Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience
Saraf, A., Yock, T. I., Niemierko, A., Oh, K. S., Curry, W. T., Butler, W. E., Forst, D. A., Arrillaga‐Romany, I., Ebb, D. H., Tarbell, N. J., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac126 · Cited by 17
CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials
Ronsley, R. J., Bertrand, K. C., Song, E. Z., Timpanaro, A., Choe, M., Tlais, D., Vitanza, N. A., & Park, J. R. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10208-4 · Cited by 17
The Blood-Brain Barrier: Implications for Experimental Cancer Therapeutics
Straehla, J. P., Reardon, D. A., Wen, P. Y., & Agar, N. Y. R. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-040433 · Cited by 17
Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?
Gatto, L., Franceschi, E., Tosoni, A., Nunno, V. D., Bartolini, S., & Brandes, A. A. (2022) · Cancers · doi:10.3390/cancers14020333 · Cited by 16
Endocrinopathy After Treatment for Medulloblastoma: Results From the SJMB03 Trial of Risk-Adapted Radiation Therapy
Merchant, T. E., Wu, S., Onar‐Thomas, A., Delaney, A., & Gajjar, A. J. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.12.016 · Cited by 15
Self-citation
MRI features of pediatric atypical teratoid rhabdoid tumors and medulloblastomas of the posterior fossa
Wu, H., Wu, C., Lin, S., Wu, C., Chen, H., Chen, Y., Lee, Y., & Chang, F. (2023) · Cancer Medicine · doi:10.1002/cam4.5780 · Cited by 15
Current Strategies for Management of Medulloblastoma
Prados, M. D. (2023) · Diagnostics · doi:10.3390/diagnostics13162622 · Cited by 17
N-of-1 Trials in Pediatric Oncology: From a Population-Based Approach to Personalized Medicine—A Review
Kyr, M., Svobodnik, A., Štěpánová, R., & Hejnová, R. (2021) · Cancers · doi:10.3390/cancers13215428 · Cited by 15
Anatomic Neuroimaging Characteristics of Posterior Fossa Type A Ependymoma Subgroups
Sabin, N. D., Hwang, S. N., Klimo, P., Chambwe, N., Tatevossian, R. G., Patni, T., Li, Y., Boop, F. A., Anderson, E., Gajjar, A., et al. (2021) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7322 · Cited by 14
Self-citation
WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?
Mani, S., Chatterjee, A., Dasgupta, A., Shirsat, N. V., Epari, S., Chinnaswamy, G., & Gupta, T. (2023) · Oncotarget · doi:10.18632/oncotarget.28360 · Cited by 14
Evolution of Systemic Therapy in Medulloblastoma Including Irradiation-Sparing Approaches
Mushtaq, N., Ain, R. U., Hamid, S. A., & Bouffet, É. (2023) · Diagnostics · doi:10.3390/diagnostics13243680 · Cited by 13
OLIG2 mediates a rare targetable stem cell fate transition in sonic hedgehog medulloblastoma
Desai, K., Wanggou, S., Luis, E., Whetstone, H., Yu, C., Vanner, R. J., Selvadurai, H. J., Lee, L., Vijay, J., Jaramillo, J. E., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54858-y · Cited by 16
Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors
Leary, S. E. S., Onar‐Thomas, A., Fangusaro, J., Gottardo, N. G., Cohen, K. J., Smith, A., Huang, A., Haas-Kogan, D. A., & Fouladi, M. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30600 · Cited by 13
Self-citation
Advancing medulloblastoma therapy: strategies and survival insights
Pan, Z., Bao, J., & Wei, S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01648-5 · Cited by 12
Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
Pribnow, A. K., Jonchère, B., Liu, J., Smith, K. S., Campagne, O., Xu, K., Robinson, S., Patel, Y. T., Onar‐Thomas, A., Wu, G., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0598 · Cited by 12
Self-citation
From sorting to sequencing in the molecular era: the evolution of the cancer stem cell model in medulloblastoma
Werbowetski‐Ogilvie, T. E. (2021) · FEBS Journal · doi:10.1111/febs.15817 · Cited by 13
Characteristics of the blood–brain barrier in pediatric brain tumors
Gao, Q., Song, D., Xu, D., Chai, X., & Ge, M. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1646641 · Cited by 11
MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice
Göbel, C., Godbole, S., Schoof, M., Holdhof, D., Kresbach, C., Loose, C., Neumann, J. E., & Schüller, U. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01654-2 · Cited by 11
Gene context drift identifies drug targets to mitigate cancer treatment resistance
Jassim, A., Nimmervoll, B. V., Terranova, S., Nathan, E., Hu, L., Taylor, J., Masih, K. E., Ruff, L., Duarte, M., Cooper, E. A., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.005 · Cited by 11
Self-citation
Ultra-low-input cell-free DNA sequencing for tumor detection and characterization in a real-world pediatric brain tumor cohort
Fischer, T. T., Maaß, K. K., Puranachot, P., Mieskolainen, M., Sill, M., Schad, P. S., Volz, S., Rosing, F., Wedig, T., Schwarz, N., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02024-w · Cited by 14
Self-citation
Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells
Zeuner, S., Vollmer, J., Sigaud, R., Oppermann, S., Peterziel, H., ElHarouni, D., Oehme, I., Witt, O., Milde, T., & Ecker, J. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04526-w · Cited by 11
Only the beginning: 50 years of progress toward curing childhood cancer
Gore, L., & O'Brien, M. M. (2024) · Cell · doi:10.1016/j.cell.2024.02.039 · Cited by 10
Outcomes of pediatric medulloblastoma in low- and middle-income countries: A retrospective analysis of 335 cases from 8 countries
Díaz-Coronado, R., Alcasabas, A. P., Baticulon, R. E., Hamid, S. A., Omran, N., Sharafeldin, H. A., Pineda, E., del Campo, R. M. N.-M., Foo, J. C., Ganesan, D., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf086 · Cited by 10
Medulloblastoma: prognostic subtypes revealed
Sidaway, P. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00478-0 · Cited by 10
Cerebellar Mutism Syndrome and Dentato-Thalamo-Cortical Tract Disruption in Diffusion Tractography Following Surgery for Medulloblastoma
Ji, Q., McAfee, S. S., Scoggins, M., Holtrop, J. L., Glass, J. O., Yuan, X., Liang, J., Li, Y., Chiang, J., Orr, B. A., et al. (2024) · Radiology · doi:10.1148/radiol.232521 · Cited by 11
Self-citation
Hypogonadism After Treatment for Medulloblastoma: Results From the SJMB03 Trial of Risk-Adapted Radiation Therapy
Merchant, T. E., Wu, S., Onar‐Thomas, A., Gajjar, A. J., & Delaney, A. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.01.001 · Cited by 9
Self-citation
Cross-species analysis of SHH medulloblastoma models reveals significant inhibitory effects of trametinib on tumor progression
Borlase, S., DeCarlo, A., Coudière-Morrison, L., Liang, L., Porter, C. J., Ramaswamy, V., & Werbowetski‐Ogilvie, T. E. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01646-0 · Cited by 8
Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours
Seiboldt, T., Zeiser, C., Nguyen, D., Çelikyürekli, S., Herter, S., Najafi, S., Stroh-Dege, A., Meulenbroeks, C., Mack, N. L., Salem-Altintas, R., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02740-5 · Cited by 11
Advancing Medulloblastoma Therapy in Pediatrics: Integrative Molecular Classification and Emerging Treatments
Kim, D. T., Uloho-Okundaye, M., Frederico, S. C., Guru, S., Kim, M. J., & Chang, S. D. (2025) · Brain Sciences · doi:10.3390/brainsci15080896 · Cited by 10
Single-cell multi-omics identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma
Veo, B. L., Wang, D., DeSisto, J. A., Pierce, A. M., Brunt, B., Bompada, P., Donson, A. M., Goodspeed, A. E., Smart, K., Foreman, N. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65466-9 · Cited by 11
Review of the impact of molecular analysis on the therapy of medulloblastoma
Sarvode, S., & Gajjar, A. J. (2023) · Pediatric Hematology Oncology Journal · doi:10.1016/j.phoj.2023.05.001 · Cited by 9
Self-citation
Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study
Fukuoka, K., Kurihara, J., Shofuda, T., Kagawa, N., Yamasaki, K., Ando, R., Ishida, J., Kanamori, M., Kawamura, A., Park, Y.-S., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01652-4 · Cited by 9
Overview and recent advances in the targeting of medulloblastoma cancer stem cells
Paul, M. R., & Zage, P. E. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1932472 · Cited by 10
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer
Forrest, S. J., Gupta, H. V., Ward, A., Li, Y. Y., Doan, D., Al‐Ibraheemi, A., Alexandrescu, S., Bandopadhayay, P., Shusterman, S., Mullen, E. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49944-0 · Cited by 13
An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival
Smith, K. S., Dhanda, S. K., Billups, C. A., Sioson, E., Lu, C., Peraza, A. Z., Gangwani, K., Li, Y., Li, Q., Lin, T., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf250 · Cited by 8
Self-citation
How do we approach the management of medulloblastoma in young children?
Lafay‐Cousin, L., Baroni, L., Ramaswamy, V., & Bouffet, É. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29838 · Cited by 9
Postoperative radiotherapy timing, molecular subgroups and treatment outcomes of Thai pediatric patients with medulloblastoma
Jaruthien, T., Nantavithya, C., Santisukwongchote, S., Shuangshoti, S., Techavichit, P., Sosothikul, D., Amornfa, J., & Shotelersuk, K. (2023) · PLoS ONE · doi:10.1371/journal.pone.0271778 · Cited by 8
Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroups
Tonn, S., Korshunov, A., Obrecht, D., Sill, M., Spohn, M., von Hoff, K., Milde, T., Pietsch, T., Goschzik, T., Bison, B., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad027 · Cited by 8
Self-citation
Optical genome mapping identifies a novel pediatric embryonal tumor with a ZNF532::NUTM1 fusion
Bornhorst, M., Eze, A., Bhattacharya, S., Putnam, E., Almira-Suarez, M. I., Rossi, C., Kambhampati, M., Almalvez, M., Barseghyan, M., Risco, N. D., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6085 · Cited by 8
Clinical, Histological, and Molecular Prognostic Factors in Childhood Medulloblastoma: Where Do We Stand?
Ntenti, C., Lallas, K., & Papazisis, G. (2023) · Diagnostics · doi:10.3390/diagnostics13111915 · Cited by 8
Verschlimmbesserung: Craniospinal Radiotherapy Is Essential in WNT Medulloblastoma Patients
Gottardo, N. G., & Gajjar, A. J. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2331 · Cited by 8
Self-citation
Normal tissue complication probability modeling to guide individual treatment planning in pediatric cranial proton and photon radiotherapy
Dell’Oro, M., Wilson, P., Short, M., Hua, C., Merchant, T. E., & Bezak, E. (2021) · Medical Physics · doi:10.1002/mp.15360 · Cited by 8
Self-citation
Temporal changes in childhood cancer incidence and survival by stage at diagnosis in Australia, 2000–2017
Youlden, D. R., Baade, P. D., Frazier, A. L., Gupta, S., Gottardo, N. G., Moore, A. S., & Aitken, J. F. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2251668 · Cited by 7
SMARCA4 Loss and Mutated β-Catenin Induce Proliferative Lesions in the Murine Embryonic Cerebellum
Göbel, C., Schoof, M., Holdhof, D., Spohn, M., & Schüller, U. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.1605-23.2024 · Cited by 7
Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtype
Massimino, M., Barretta, F., Dossena, C., Minasi, S., Buttarelli, F. R., Biassoni, V., Oriani, M., Schiavello, E., Ficorilli, M., Nigro, O., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae189 · Cited by 7
Treatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children’s Cancer Group (CCCG)
Liu, A. P. Y., Zhen, Z., Yang, Q., Yuan, X., Ma, X., Chen, J., Wang, J., Yang, L., Guo, H., Jiang, L., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab134 · Cited by 7
Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study
Lucas, J. T., Tinkle, C. L., Huang, J., Onar‐Thomas, A., Srinivasan, S., Tumlin, P., Becksfort, J. B., Klimo, P. D., Boop, F. A., Robinson, G. W., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab284 · Cited by 7
Self-citation
Questions and answers in the management of children with medulloblastoma over the time. How did we get here? A systematic review
Osuna‐Marco, M. P., Martín‐López, L. I., Tejera, Á. M., & López‐Ibor, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1229853 · Cited by 7
Targeting synthetic lethality between non-homologous end joining and radiation in very-high-risk medulloblastoma
DeCarlo, A., MacLeod, G. D. A. H., da Silva, C. F., Shen, L., Povilaikaite, J., Deane, M., Aragao, L., Sie, M., Termini, D., Magee, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102202 · Cited by 6
Self-citation
Innovative machine learning approach for liver fibrosis and disease severity evaluation in MAFLD patients using MRI fat content analysis
Hou, M., Zhu, Y., Zhou, H., Zhou, S., Zhang, J., Zhang, Y., & Liu, X. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01818-5 · Cited by 7
WNT‐activated, MYC ‐amplified medulloblastoma displaying intratumoural heterogeneity
Green, S. T., Hoover, T., Doss, D., Davidow, K. A., Walter, A. W., Cottrell, C. E., & Mahapatra, S. (2023) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12945 · Cited by 4
Medulloblastoma Molecular Subgrouping and Outcomes Data of a Single Center From a Low‐ and Middle‐Income Country
Mushtaq, N., Bashir, F., Zahid, S., Riaz, Q., Javed, G., Tariq, M., Qureshi, B. M., Hilal, K., Ramaswamy, V., Hawkins, C. E., et al. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31555 · Cited by 6
Therapeutic radiation drives leptomeningeal dissemination of medulloblastoma through an innate immune process
Nör, C., Kharas, K., Rasnitsyn, A., Vladoiu, M. C., Cho, N. W., Young, J. S., Nör, F., Mankahla, N., Haapasalo, J. A., Nordfors, K., et al. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.06.016 · Cited by 7
Effects of different molecular subtypes and tumor biology on the prognosis of medulloblastoma
Aras, Y., Dölen, D., Çelik, A. İ., Kayhan, G. K., Kebudi, R., Ünverengil, G., Sabancı, P. A., & İzgi, N. (2021) · Child s Nervous System · doi:10.1007/s00381-021-05350-1 · Cited by 6
The Site of Origin of Medulloblastoma: Surgical Observations Correlated to Molecular Groups
Ciobanu-Caraus, O., Czech, T., Peyrl, A., Haberler, C., Kasprian, G. J., Furtner, J., Kool, M., Sill, M., Frischer, J. M., Cho, A., et al. (2023) · Cancers · doi:10.3390/cancers15194877 · Cited by 6
Clinico-Radiological Outcomes in WNT-Subgroup Medulloblastoma
Mani, S., Chatterjee, A., Dasgupta, A., Shirsat, N. V., Pawar, A., Epari, S., Sahay, A., Sahu, A., Moiyadi, A. V., Prasad, M., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14040358 · Cited by 5
Radiotherapy for Recurrent Medulloblastoma in Children and Adolescents: Survival after Re-Irradiation and First-Time Irradiation
Adolph, J. E., Fleischhack, G., Tschirner, S., Rink, L., Dittes, C., Mikasch, R., Dammann, P. R., Mynarek, M., Obrecht, D., Rutkowski, S., et al. (2024) · Cancers · doi:10.3390/cancers16111955 · Cited by 5
Self-citation
Building pediatric neuro-oncology capacity in LMICs through multidisciplinary education and collaboration: a mixed-methods analysis
Berg, F., Bryan, G., Andujar, A., Graetz, D. E., Galindo, C. R., Qaddoumi, I. A., & Moreira, D. C. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf153 · Cited by 5

Authors: Gajjar, A., Robinson, G. W., Smith, K. S., Lin, T., Merchant, T. E., Chintagumpala, M., Mahajan, A., Su, J., Bouffet, E., Bartels, U., Schechter, T., Hassall, T., Robertson, T., Nicholls, W., Gururangan, S., Schroeder, K., Sullivan, M., Wheeler, G., Hansford, J. R., Kellie, S. J., McCowage, G., Cohn, R., Fisher, M. J., Krasin, M. J., Stewart, C. F., Broniscer, A., Buchhalter, I., Tatevossian, R. G., Orr, B. A., Neale, G., Klimo, P., Boop, F., Srinivasan, A., Pfister, S. M., Gilbertson, R. J., Onar-Thomas, A., Ellison, D. W., & Northcott, P. A.
Affiliations: St. Jude Children's Research Hospital (US)
Baylor College of Medicine (US)
Mayo Clinic (US)
Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON
University of Toronto (CA)
The University of Queensland (AU)
UF Health Shands Hospital (US)
Duke University (US)
Royal Children's Hospital (AU)
The University of Melbourne (AU)
The University of Sydney (AU)
UNSW Sydney (AU)
Children's Hospital of Philadelphia (US)
University of Pittsburgh (US)
German Cancer Research Center (DE)
Hartwell Center, St Jude Children's Research Hospital, Memphis, TN
University of Tennessee Health Science Center (US)
Cancer Research UK (GB)
Department of Radiation Oncology, St Jude Children's Research Hospital, Memphis, TN
ORCID: Gajjar, Amar
Robinson, Giles W.
Smith, Kyle S.
Lin, Tong
Merchant, Thomas E.
Chintagumpala, Murali
Mahajan, Anita
Su, Jack
Bouffet, Eric
Bartels, Ute
Schechter, Tal
Hassall, Tim
Robertson, Thomas
Nicholls, Wayne
Gururangan, Sridharan
Schroeder, Kristin
Sullivan, Michael
Hansford, Jordan R.
McCowage, Geoffrey
Cohn, Richard
Fisher, Michael J.
Krasin, Matthew J.
Stewart, Clinton F.
Broniscer, Alberto
Buchhalter, Ivo
Tatevossian, Ruth G.
Orr, Brent A.
Neale, Geoff
Klimo, Paul
Boop, Frederick
Srinivasan, Ashok
Pfister, Stefan M.
Gilbertson, Richard J.
Ellison, David W.
Northcott, Paul A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2021-03-01
Volume: 39
Issue: 7
Pages: 822-835
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.20.01372
PMC: PMC10166353
OpenAlex: W3118854714
Cited by: 241
References: 28
Citations by year: 2026: 33 · 2025: 63 · 2024: 38 · 2023: 52 · 2022: 33 · 2021: 21
FWCI: 20.50
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Minerva Access (University of Melbourne) (submittedVersion)
Funders: AstraZeneca
Cancer Research UK (26398)
Brain Tumour Charity (GN-000575)
Genentech
National Cancer Institute (P30CA021765)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords: medulloblastoma, risk-adapted treatment, molecular classification, Group 3 medulloblastoma, Group 4 medulloblastoma, DNA methylation profiling, CTNNB1 mutation, PTCH1 mutation, TP53 mutation, SMARCA4 mutation, progression-free survival, pediatric brain tumors
MeSH terms: Progression-Free Survival, Epigenome, Adolescent, Cerebellar Neoplasms, Child, Child, Preschool, DNA Mutational Analysis, Female, Humans, Magnetic Resonance Imaging, Male, Medulloblastoma, Mutation, Predictive Value of Tests, Risk Factors, Time Factors, Biomarkers, Tumor, Risk Assessment, DNA Methylation, Young Adult, Epigenomics, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks